| abstract |
The present invention relates to a structural HCV antigen, a functional part of the structural antigen or a recombinant MVA capable of expressing an epitope of the structural antigen. The invention further relates to pharmaceutical compositions, particularly in the form of vaccines, comprising the recombinant MVA of the invention, to eukaryotic cells comprising the recombinant MVA of the invention, and various uses of the recombinant MVA, For example, it relates to a drug suitable for the production of recombinant structural proteins, the treatment and prevention of HCV infection and the diseases caused thereby. The invention further relates to a method for producing a recombinant MVA, a recombinant HCV structural polypeptide encoded by the recombinant MVA, and the DNA or RNA of the recombinant MVA. |